CA2405479C - Method of inhibiting the expression of inflammatory cytokines and chemokines - Google Patents
Method of inhibiting the expression of inflammatory cytokines and chemokines Download PDFInfo
- Publication number
- CA2405479C CA2405479C CA2405479A CA2405479A CA2405479C CA 2405479 C CA2405479 C CA 2405479C CA 2405479 A CA2405479 A CA 2405479A CA 2405479 A CA2405479 A CA 2405479A CA 2405479 C CA2405479 C CA 2405479C
- Authority
- CA
- Canada
- Prior art keywords
- astaxanthin
- chemokines
- expression
- inflammatory cytokines
- inhibiting
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 102000004127 Cytokines Human genes 0.000 title claims abstract description 27
- 108090000695 Cytokines Proteins 0.000 title claims abstract description 27
- 230000014509 gene expression Effects 0.000 title claims abstract description 27
- 230000002757 inflammatory effect Effects 0.000 title claims abstract description 27
- 102000019034 Chemokines Human genes 0.000 title claims abstract description 26
- 108010012236 Chemokines Proteins 0.000 title claims abstract description 26
- 230000002401 inhibitory effect Effects 0.000 title claims abstract description 21
- 238000000034 method Methods 0.000 title abstract description 10
- JEBFVOLFMLUKLF-IFPLVEIFSA-N Astaxanthin Natural products CC(=C/C=C/C(=C/C=C/C1=C(C)C(=O)C(O)CC1(C)C)/C)C=CC=C(/C)C=CC=C(/C)C=CC2=C(C)C(=O)C(O)CC2(C)C JEBFVOLFMLUKLF-IFPLVEIFSA-N 0.000 claims abstract description 50
- 235000013793 astaxanthin Nutrition 0.000 claims abstract description 50
- 239000001168 astaxanthin Substances 0.000 claims abstract description 50
- MQZIGYBFDRPAKN-ZWAPEEGVSA-N astaxanthin Chemical compound C([C@H](O)C(=O)C=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)[C@@H](O)CC1(C)C MQZIGYBFDRPAKN-ZWAPEEGVSA-N 0.000 claims abstract description 50
- 229940022405 astaxanthin Drugs 0.000 claims abstract description 50
- 241001465754 Metazoa Species 0.000 claims abstract description 21
- 239000003814 drug Substances 0.000 claims abstract description 14
- 230000004913 activation Effects 0.000 claims description 17
- 239000000203 mixture Substances 0.000 claims description 6
- 241000168525 Haematococcus Species 0.000 claims description 5
- 108010002352 Interleukin-1 Proteins 0.000 claims description 4
- 101710151803 Mitochondrial intermediate peptidase 2 Proteins 0.000 claims description 3
- 230000037396 body weight Effects 0.000 claims description 3
- 239000004480 active ingredient Substances 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 235000008210 xanthophylls Nutrition 0.000 abstract description 13
- KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 abstract description 12
- 229960005375 lutein Drugs 0.000 abstract description 12
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 abstract description 12
- FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 abstract description 12
- 230000000069 prophylactic effect Effects 0.000 abstract description 6
- 230000001225 therapeutic effect Effects 0.000 abstract description 6
- 230000005764 inhibitory process Effects 0.000 abstract description 5
- -1 astaxanthin Chemical compound 0.000 abstract description 4
- 238000002360 preparation method Methods 0.000 abstract description 4
- 210000004027 cell Anatomy 0.000 description 16
- 108700008625 Reporter Genes Proteins 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 239000013612 plasmid Substances 0.000 description 6
- 238000001890 transfection Methods 0.000 description 6
- 230000000694 effects Effects 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 102100029064 Serine/threonine-protein kinase WNK1 Human genes 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 3
- 239000012894 fetal calf serum Substances 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 3
- 241000195493 Cryptophyta Species 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 108090000331 Firefly luciferases Proteins 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 108010001859 Proto-Oncogene Proteins c-rel Proteins 0.000 description 2
- 102000000850 Proto-Oncogene Proteins c-rel Human genes 0.000 description 2
- 108010052090 Renilla Luciferases Proteins 0.000 description 2
- 102000040945 Transcription factor Human genes 0.000 description 2
- 108091023040 Transcription factor Proteins 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102100040247 Tumor necrosis factor Human genes 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 238000003670 luciferase enzyme activity assay Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 210000004940 nucleus Anatomy 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 230000005945 translocation Effects 0.000 description 2
- 102000011767 Acute-Phase Proteins Human genes 0.000 description 1
- 108010062271 Acute-Phase Proteins Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000238424 Crustacea Species 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 241000254158 Lampyridae Species 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 102000003945 NF-kappa B Human genes 0.000 description 1
- 108010057466 NF-kappa B Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 239000000074 antisense oligonucleotide Substances 0.000 description 1
- 238000012230 antisense oligonucleotides Methods 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000010057 immune-inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 108091006086 inhibitor proteins Proteins 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000005865 ionizing radiation Effects 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 210000000633 nuclear envelope Anatomy 0.000 description 1
- 230000005937 nuclear translocation Effects 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 239000003642 reactive oxygen metabolite Substances 0.000 description 1
- 230000006697 redox regulation Effects 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 239000012096 transfection reagent Substances 0.000 description 1
- 238000003146 transient transfection Methods 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 125000000264 xanthophyll group Chemical group 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/02—Algae
- A61K36/05—Chlorophycota or chlorophyta (green algae), e.g. Chlorella
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Rheumatology (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Alternative & Traditional Medicine (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0001071A SE0001071D0 (sv) | 2000-03-27 | 2000-03-27 | Method of inhibiting the expression of inflammatory cytokines and chemokines |
| SE0001071-0 | 2000-03-27 | ||
| PCT/SE2001/000600 WO2001072296A1 (en) | 2000-03-27 | 2001-03-21 | Method of inhibiting the expression of inflammatory cytokines and chemokines |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2405479A1 CA2405479A1 (en) | 2001-10-04 |
| CA2405479C true CA2405479C (en) | 2010-11-16 |
Family
ID=20279020
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2405479A Expired - Fee Related CA2405479C (en) | 2000-03-27 | 2001-03-21 | Method of inhibiting the expression of inflammatory cytokines and chemokines |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP1267857B1 (enExample) |
| JP (1) | JP2003528139A (enExample) |
| AT (1) | ATE353639T1 (enExample) |
| AU (1) | AU2001242965A1 (enExample) |
| CA (1) | CA2405479C (enExample) |
| DE (1) | DE60126591D1 (enExample) |
| SE (1) | SE0001071D0 (enExample) |
| WO (1) | WO2001072296A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2002349784A1 (en) * | 2001-12-03 | 2003-06-17 | Asahi Kasei Pharma Corporation | Nf-kappab activating genes |
| EP2653157B1 (en) * | 2004-02-04 | 2016-08-03 | Fuji Chemical Industry Co., Ltd. | Astaxanthin for improving muscle atrophy |
| JP2006008714A (ja) * | 2005-03-17 | 2006-01-12 | Yamaha Motor Co Ltd | マトリックスメタロプロテイナーゼ阻害剤 |
| JP2006008718A (ja) * | 2005-06-03 | 2006-01-12 | Yamaha Motor Co Ltd | シクロオキシゲナーゼ活性阻害剤 |
| JP2006008719A (ja) * | 2005-06-23 | 2006-01-12 | Yamaha Motor Co Ltd | 血中過酸化脂質抑制剤 |
| WO2008106606A2 (en) * | 2007-02-28 | 2008-09-04 | Cardax Pharmaceuticals, Inc. | Carotenoid analogs and derivatives in the treatment of prostate cancer |
| US7805004B2 (en) * | 2007-02-28 | 2010-09-28 | Microsoft Corporation | Radical set determination for HMM based east asian character recognition |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH05155736A (ja) * | 1991-12-10 | 1993-06-22 | Nakano Seiyaku Kk | 化粧料 |
| JPH0799924A (ja) * | 1993-09-30 | 1995-04-18 | Nippon Suisan Kaisha Ltd | アスタキサンチンを主要成分とするファフィア色素油の安定な粉末化物及びその製造方法 |
| JPH07300421A (ja) * | 1994-04-28 | 1995-11-14 | Itano Reitou Kk | 抗炎症剤 |
| US5527533A (en) * | 1994-10-27 | 1996-06-18 | Board Of Trustees Of The University Of Illinois | Method of retarding and ameliorating central nervous system and eye damage |
| EP0806946A2 (de) * | 1995-02-03 | 1997-11-19 | Basf Aktiengesellschaft | Verwendung von carotinoiden zur herstellung von arzneimitteln zur behandlung von dermatosen |
| JPH09124470A (ja) * | 1995-10-26 | 1997-05-13 | Suntory Ltd | 抗ストレス組成物 |
| JPH09143063A (ja) * | 1995-11-22 | 1997-06-03 | Kose Corp | 外用に適する組成物 |
| SE522246C2 (sv) * | 1997-02-27 | 2004-01-27 | Astacarotene Ab | Oralt preparat för profylaktisk och terapeutisk behandling av Helicobacter Sp. infektion |
| WO1998045241A2 (en) * | 1997-04-04 | 1998-10-15 | Henkel Corporation | Lutein esters having high bioavailability |
| SE512531C2 (sv) * | 1997-09-04 | 2000-03-27 | Astacarotene Ab | Användning av åtminstone en typ av xantofyller för framställning av ett läkemedel för profylaktisk och/eller terapeutisk förbättring av muskelfunktionsdurationen hos däggdjur och/eller behandling av muskelstörningar eller - sjukdomar hos däggdjur |
-
2000
- 2000-03-27 SE SE0001071A patent/SE0001071D0/xx unknown
-
2001
- 2001-03-21 JP JP2001570257A patent/JP2003528139A/ja active Pending
- 2001-03-21 DE DE60126591T patent/DE60126591D1/de not_active Expired - Fee Related
- 2001-03-21 AU AU2001242965A patent/AU2001242965A1/en not_active Abandoned
- 2001-03-21 AT AT01916022T patent/ATE353639T1/de not_active IP Right Cessation
- 2001-03-21 WO PCT/SE2001/000600 patent/WO2001072296A1/en not_active Ceased
- 2001-03-21 CA CA2405479A patent/CA2405479C/en not_active Expired - Fee Related
- 2001-03-21 EP EP01916022A patent/EP1267857B1/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| CA2405479A1 (en) | 2001-10-04 |
| JP2003528139A (ja) | 2003-09-24 |
| ATE353639T1 (de) | 2007-03-15 |
| DE60126591D1 (de) | 2007-03-29 |
| SE0001071D0 (sv) | 2000-03-27 |
| EP1267857A1 (en) | 2003-01-02 |
| AU2001242965A1 (en) | 2001-10-08 |
| WO2001072296A1 (en) | 2001-10-04 |
| EP1267857B1 (en) | 2007-02-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Li et al. | Synergistic anti‐inflammatory effects of quercetin and catechin via inhibiting activation of TLR4–MyD88‐mediated NF‐κB and MAPK signaling pathways | |
| Ay et al. | Molecular mechanisms underlying protective effects of quercetin against mitochondrial dysfunction and progressive dopaminergic neurodegeneration in cell culture and MitoPark transgenic mouse models of Parkinson's Disease | |
| Barbarestani et al. | Effects of dietary lavender essential oil on growth performance, intestinal function, and antioxidant status of broiler chickens | |
| Ables et al. | Pleiotropic responses to methionine restriction | |
| Yang et al. | Green tea polyphenols block endotoxin-induced tumor necrosis factor-production and lethality in a murine model | |
| Ming et al. | Effects of emodin and vitamin C on growth performance, biochemical parameters and two HSP70s mRNA expression of Wuchang bream (Megalobrama amblycephala Yih) under high temperature stress | |
| Wang et al. | Seaweed extracts and unsaturated fatty acid constituents from the green alga Ulva lactuca as activators of the cytoprotective Nrf2–ARE pathway | |
| Yang et al. | Activation of Nrf2 by phloretin attenuates palmitic acid-induced endothelial cell oxidative stress via AMPK-dependent signaling | |
| Casaburi et al. | Potential of olive oil phenols as chemopreventive and therapeutic agents against cancer: a review of in vitro studies | |
| Yang et al. | Psoralidin, a dual inhibitor of COX-2 and 5-LOX, regulates ionizing radiation (IR)-induced pulmonary inflammation | |
| US7078040B2 (en) | Method of inhibiting the expression of inflammatory cytokines and chemokines | |
| Wan et al. | Protective effects of lycopene on mitochondrial oxidative injury and dysfunction in the liver of aflatoxin B1-exposed broilers | |
| Deng et al. | Magnolol and honokiol regulate the calcium-activated potassium channels signaling pathway in Enterotoxigenic Escherichia coli-induced diarrhea mice | |
| Martorana et al. | Differential Modulation of NF‐κB in Neurons and Astrocytes Underlies Neuroprotection and Antigliosis Activity of Natural Antioxidant Molecules | |
| Liu et al. | Cytochrome P450 enzymes mediated by DNA methylation is involved in deoxynivalenol-induced hepatoxicity in piglets | |
| CA2405479C (en) | Method of inhibiting the expression of inflammatory cytokines and chemokines | |
| Choi et al. | Anti-inflammatory potential of peat moss extracts in lipopolysaccharide-stimulated RAW 264.7 macrophages | |
| Lee et al. | Effect of dietary supplementation of the combination of gallic and linoleic acid in thigh meat of broilers | |
| Li et al. | Ellagic acid alters muscle fiber-type composition and promotes mitochondrial biogenesis through the AMPK signaling pathway in healthy pigs | |
| Meng et al. | β-carotene alleviates LPS-induced inflammation through regulating STIM1/ORAI1 expression in bovine mammary epithelial cells | |
| Nagai et al. | Anti-obesity effects of Asian dayflower, Commelina communis, in mice with high-fat diet-induced obesity and in 3T3-L1 cells | |
| Li et al. | PGC-1α Promotes mitochondrial biosynthesis and energy metabolism of goose fatty liver | |
| Kim et al. | Nargenicin enhances 1, 25-dihydroxyvitamin D3-and all-trans retinoic acid-induced leukemia cell differentiation via PKCβI/MAPK pathways | |
| Das et al. | Effect of γ-linolenic acid and prostaglandins E1 on gamma-radiation and chemical-induced genetic damage to the bone marrow cells of mice | |
| Zhao et al. | Blueberry Polyphenol Extracts Enhance the Intestinal Antioxidant Capacity in Weaned Rats by Modulating the Nrf2–Keap1 Signal Pathway |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |
Effective date: 20180321 |